https://lgh447inhibitor.com/th....e-function-involving
As an anti-PD-1 antibody, camrelizumab (SHR-121 has some unwanted effects in tumor immunotherapy. The most common unpleasant event is reactive capillary hemangioma. While it is commonly reported to happen within the skin, gingival reactive capillary hemangioma is seldom reported. CASE OVERVIEW A 54-year-old guy reported of gingival overgrowth on the anterior facet of the maxilla and mandible for more than 6 mo. He had been added to SHR-1210 for lung cancer for 7 mo. A gingival m
Like
Comment
Share
